WallStreetZenWallStreetZen

NASDAQ: AKRO
Akero Therapeutics Inc Stock

$32.33+1.50 (+4.87%)
Updated Nov 1, 2024
AKRO Price
$32.33
Fair Value Price
$3.96
Market Cap
$2.24B
52 Week Low
$13.39
52 Week High
$37.00
P/E
-9.4x
P/B
2.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$204.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$191M
Beta
0.9
Next Earnings
Nov 11, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AKRO Overview

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AKRO ($32.33) is overvalued by 716.44% relative to our estimate of its Fair Value price of $3.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AKRO ($32.33) is not significantly undervalued (716.44%) relative to our estimate of its Fair Value price of $3.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AKRO due diligence checks available for Premium users.

Be the first to know about important AKRO news, forecast changes, insider trades & much more!

AKRO News

Valuation

AKRO fair value

Fair Value of AKRO stock based on Discounted Cash Flow (DCF)
Price
$32.33
Fair Value
$3.96
Overvalued by
716.44%
AKRO ($32.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKRO ($32.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AKRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AKRO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.4x
Industry
-103.77x
Market
22.22x

AKRO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
5.8x
AKRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AKRO's financial health

Profit margin

Revenue
$0.0
Net Income
-$56.0M
Profit Margin
0%
AKRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$865.0M
Liabilities
$67.0M
Debt to equity
0.08
AKRO's short-term assets ($776.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKRO's short-term assets ($776.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AKRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$57.5M
Investing
-$255.9M
Financing
-$150.0k
AKRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AKRO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AKRO$2.24B+4.87%-9.40x2.81x
KROS$2.25B+3.27%-11.68x5.34x
SWTX$2.27B+1.63%-6.90x4.08x
SRRK$2.27B-0.07%-12.80x17.02x
SLNO$2.17B+1.45%-30.69x7.73x

Akero Therapeutics Stock FAQ

What is Akero Therapeutics's quote symbol?

(NASDAQ: AKRO) Akero Therapeutics trades on the NASDAQ under the ticker symbol AKRO. Akero Therapeutics stock quotes can also be displayed as NASDAQ: AKRO.

If you're new to stock investing, here's how to buy Akero Therapeutics stock.

What is the 52 week high and low for Akero Therapeutics (NASDAQ: AKRO)?

(NASDAQ: AKRO) Akero Therapeutics's 52-week high was $37.00, and its 52-week low was $13.39. It is currently -12.62% from its 52-week high and 141.47% from its 52-week low.

How much is Akero Therapeutics stock worth today?

(NASDAQ: AKRO) Akero Therapeutics currently has 69,430,754 outstanding shares. With Akero Therapeutics stock trading at $32.33 per share, the total value of Akero Therapeutics stock (market capitalization) is $2.24B.

Akero Therapeutics stock was originally listed at a price of $18.32 in Jun 20, 2019. If you had invested in Akero Therapeutics stock at $18.32, your return over the last 5 years would have been 76.47%, for an annualized return of 12.03% (not including any dividends or dividend reinvestments).

How much is Akero Therapeutics's stock price per share?

(NASDAQ: AKRO) Akero Therapeutics stock price per share is $32.33 today (as of Nov 1, 2024).

What is Akero Therapeutics's Market Cap?

(NASDAQ: AKRO) Akero Therapeutics's market cap is $2.24B, as of Nov 2, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Akero Therapeutics's market cap is calculated by multiplying AKRO's current stock price of $32.33 by AKRO's total outstanding shares of 69,430,754.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.